CTI(300012) 新浪财经·2025-04-22 00:33Core Insights - The company reported a revenue of 6.084 billion yuan for 2024, representing a year-on-year growth of 8.55% [1] - The net profit attributable to shareholders was 921 million yuan, with a year-on-year increase of 1.19% [1] - The company achieved a non-dedicated net profit of 860 million yuan, reflecting a year-on-year growth of 9.79% [1] Revenue Breakdown - The revenue from the life sciences segment was 2.841 billion yuan, growing by 13.75% year-on-year [1] - The industrial testing segment generated 1.204 billion yuan, with a year-on-year increase of 10.32% [1] - The consumer products segment achieved 988 million yuan, showing a slight growth of 0.88% year-on-year [1] - The trade assurance segment reported 764 million yuan, with a year-on-year growth of 9.19% [1] - The pharmaceutical and medical testing segment faced a decline, generating 287 million yuan, down 14.71% year-on-year [1] Profitability Metrics - The company's gross margin was 49.47%, reflecting a slight increase of 1.41 percentage points year-on-year [2] - The net profit margin was 15.33%, showing a slight decline of 1.21 percentage points year-on-year [2] - The gross margins for different segments were as follows: life sciences at 50.42%, industrial testing at 45.25%, consumer products at 43.53%, trade assurance at 71.21%, and pharmaceutical and medical services at 20.43% [2] Future Outlook - The company is expected to achieve revenues of 6.965 billion yuan, 8.124 billion yuan, and 9.22 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of approximately 14%, 17%, and 14% [3] - The net profit attributable to shareholders is projected to be 1.093 billion yuan, 1.275 billion yuan, and 1.479 billion yuan for the same years, with growth rates of about 19%, 17%, and 16% [3] - The company maintains a strong competitive advantage in traditional sectors and is expected to drive business growth through proactive innovation [3]